Premier Alternatives

Solarea Bio

Drug Discovery · Waltham, MA · Founded 2017 · Privately Held (backing)

Developer of microbiome-based health products designed to address age-related inflammatory conditions and improve overall health. Solarea Bio is based in Waltham, MA and was founded in 2017. It was valued at $37 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $37.4 million across 4 recorded rounds; the latest was a $9.9 million early-stage round in Nov 2025.

PMV mark · valuation
$37.0M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$37.4M
Last round
Early Stage VC
Nov 2025

Solarea Bio key facts

as of Oct 2026
  • Developer of microbiome-based health products designed to address age-related inflammatory conditions and improve overall health.
  • Solarea Bio is valued at approximately $37.0M as of Oct 2026, set at its later-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $37.4M across 4 recorded rounds; the latest was Early Stage VC ($9.9M) in Nov 2025.
  • Notable investors include Viking Global Investors, Joyance Partners, Olive Tree Capital, S2G Investments, BOLD Capital Partners — 12 tracked in total.
  • Solarea Bio has filed 4 Form Ds with the SEC since 2020, most recently Nov 2025 ($9.9M sold to 5 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$37.0M

Valued at $37.0M at its later-stage round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Solarea Bio with a free account
  • ·The complete investor list: 12 names
  • ·Watch Solarea Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Solarea Bio funding rounds

4 rounds
Nov 2025Early Stage VC$9.9MSEC filing▮
Aug 2024Seed Round$1.0MSEC filing▮
May 2023Later Stage VC (Series B)$15.0M▮
Sep 2020Early Stage VC (Series A)$11.3M▮
Full funding history →

Solarea Bio valuation

Solarea Bio was valued at $37 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Solarea Bio raised?

Solarea Bio has raised $37.4 million across 4 recorded rounds since 2020. The largest was a $9.9 million early-stage round in Nov 2025.

Solarea Bio has filed 4 Form Ds with the SEC since 2020, most recently in Nov 2025 ($9.9 million sold to 5 investors).

Solarea Bio investors

12 investors are on record for Solarea Bio, including Viking Global Investors, Joyance Partners, Olive Tree Capital and S2G Investments. By type, the record holds 6 venture capital firms, 1 family office and 1 asset manager. The early-stage round in Nov 2025 drew 5 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Hinge Bio ($46 million), ParcelBio ($41.2 million) and Persephone Biosciences ($37.3 million).

About Solarea Bio

Developer of microbiome-based health products designed to address age-related inflammatory conditions and improve overall health. The company offers microbial solutions derived from bacteria and fungi found in fruits and vegetables, supported by proprietary isolation technology and a structured development pipeline, enabling individuals with inflammatory and age-related conditions to manage symptoms and support long-term health.

Industry
Drug Discovery
Sector
Healthcare
HQ
Waltham, MA, United States
Founded
2017
Employees
19
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.